Enoxaparin

Drug Levels and Effects:




Summary of Use during Lactation:


Limited information indicates that maternal enoxaparin in doses up to 40 mg daily do not to cause any adverse effects in breastfed infants. Because its large molecular weight of 2000 to 8000 daltons, enoxaparin would not be expected to be excreted into breasmilk or to be absorbed from breastmilk by the infant. No special precautions are required.


Drug Levels:


Maternal Levels.

Relevant published information was not found as of the revision date.

Infant Levels.

Relevant published information was not found as of the revision date.


Effects in Breastfed Infants:


Ten women received enoxaparin 20 mg and 2 received 40 mg daily by subcutaneous injection from the prepartum to the postpartum period. At 5 to 7 days postpartum, anti-Xa activity (a measurement of enoxaparinanticoagulantactivity) was undetectable in their 12 completely breastfed term neonates 1.5 to 3 hours after they were breastfed for at least 5 days. No bleeding was detected among the infants during maternal enoxaparin therapy.


Possible Effects on Lactation:


Relevant published information was not found as of the revision date.


Alternate Drugs to Consider:


Dalteparin,Lepirudin


References:


1. Guillonneau M, de Crepy A, Aufrant C et al. [Breast-feeding is possible in case of maternal treatment with enoxaparin]. Arch Pediatr (Paris). 1996;3:513-4. PMID:8763733



Substance Identification:




Substance Name:

Enoxaparin

CAS Registry Number:

679809-58-6

Drug Class:


Anticoagulants
  • Low Molecular Weight Heparin


  • Administrative Information:




    LactMed Record Number:


    104


    Last Revision Date:


    Disclaimer:Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.